Oxford Biomedica Hosts Free Webinar on AAV Expertise
Oxford Biomedica, a prominent player in cell and gene therapy contract development and manufacturing, is excited to announce a free 60-minute webinar that will highlight its cutting-edge capabilities in adeno-associated virus (AAV) development. This event aims to share valuable insights into their recent advancements in AAV technology.
Webinar Information and Key Presenters
The upcoming webinar, titled “Advanced AAV Processing and Potency through Characterisation of Capsid and Payload Heterogeneity”, is set for September 11. Attendees will have the opportunity to hear from a panel of distinguished speakers:
Featured Speakers
- Sarah Laughlin-Toth, PhD, Senior Scientist, Analytical Development at Oxford Biomedica
- Thomas Thiers, Downstream Scientist, Purification Sciences at Oxford Biomedica
- Alex Meola, Associate Director, AAV Downstream Process Development at Oxford Biomedica
The Importance of AAV Characterisation
The speakers will explore the significance of advanced characterisation of AAV capsids and how this impacts product quality and effectiveness. They will discuss several key factors, including:
Effects of Capsid Modifications
Topics will cover the impact of capsid modifications such as VP1 deamidation, the conditions of bioreactor production, and capsid heterogeneity on AAV products.
This discussion is vital for improving the development and manufacturing processes of AAV-based therapies. Enhancements in these areas could lead to more effective treatments and greater patient safety.
Webinar Timing and How to Register
The webinar is scheduled to begin at 16:00 BST. After the presentations, there will be a live Q&A session, providing attendees the chance to interact with the experts. You can register through the company’s official website.
About Oxford Biomedica
Oxford Biomedica plc (LSE: OXB) is a renowned contract development and manufacturing organization (CDMO) specializing in the cell and gene therapy field. The company is dedicated to empowering its partners to deliver transformative therapies to patients around the globe.
With a legacy of over 25 years as pioneers in this domain, OXB has extensive experience in developing and manufacturing viral vectors. The organization collaborates with top pharmaceutical and biotechnology companies to offer comprehensive solutions in viral vector development, particularly focusing on lentivirus and AAV technologies.
Exceptional Manufacturing Capabilities
Oxford Biomedica's expertise spans from early-stage development to commercialisation, supported by rigorous quality assurance, analytical methods, and regulatory knowledge. Their innovative technologies include a state-of-the-art 4th generation lentiviral vector system and advanced AAV production techniques.
Based in Oxford, UK, Oxford Biomedica operates bioprocessing and manufacturing facilities in various locations, including parts of France and near Boston, MA.
Contact Information
For Inquiries:
Oxford Biomedica plc:
Sebastien Ribault, Chief Commercial Officer – T: +44 (0) 1865 509 737 / E: partnering@oxb.com
For more information about Oxford Biomedica's initiatives, please visit their official website and follow their updates on social media.
Frequently Asked Questions
What topics will be covered in the Oxford Biomedica webinar?
The webinar will focus on advanced AAV processing and the significance of capsid characterisation in the development of therapies.
Who are the speakers for this event?
The speakers include Sarah Laughlin-Toth, Thomas Thiers, and Alex Meola, all representing Oxford Biomedica.
What are the benefits of attending the webinar?
Participants will gain insights into advancements in AAV technology that could improve therapy efficacy and safety.
How can I register for the webinar?
You can register for the webinar through the official Oxford Biomedica website.
What is the mission of Oxford Biomedica?
Oxford Biomedica's mission is to empower its clients to provide life-changing therapies to patients worldwide.
